Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT00352885
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Immunization in Patients with Metastatic Melanoma
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1230
- Registration Number
- NCT00338377
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer
- Conditions
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2012-03-09
- Lead Sponsor
- Endocyte
- Target Recruit Count
- 13
- Registration Number
- NCT00329368
- Locations
- 🇺🇸
Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸Great Lakes Cancer Institute Breslin Cancer Center, Lansing, Michigan, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Oxford BioMedica
- Target Recruit Count
- 25
- Registration Number
- NCT00325507
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies
- Locations
- 🇺🇸
NIH Intramural Research Program ACTG CRS, Bethesda, Maryland, United States
Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
- Conditions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2006-02-16
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 456
- Registration Number
- NCT00291369
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 40
- Registration Number
- NCT00203866
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-09-20
- Target Recruit Count
- 60
- Registration Number
- NCT00196651
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT00186862
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00136448
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.